<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02560558</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082511</org_study_id>
    <nct_id>NCT02560558</nct_id>
  </id_info>
  <brief_title>Bela 8 Week Dosing</brief_title>
  <official_title>Belatacept Immunosuppression Therapy in Post-Transplant Kidney Recipients: Comparison of 4-Week and 8-Week Dosing Intervals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to transition patients who have been stable on Belatacept for&#xD;
      one year after kidney transplant from standard 4-week to an investigational 8-week belatacept&#xD;
      dosing schedule. The investigators hypothesize that renal function and acute rejection rates&#xD;
      will be non-inferior with 8-week belatacept dosing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current dosing protocol for patients who have undergone a kidney transplant requires that&#xD;
      Belatacept be given as an infusion every 4 weeks. The investigator wants to assess if the&#xD;
      patients who have been stable for one year after transplant can be safely transitioned to an&#xD;
      8-week Belatacept infusion schedule. Renal function and any episodes of acute rejection will&#xD;
      be closely monitored.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2015</start_date>
  <completion_date type="Actual">August 29, 2019</completion_date>
  <primary_completion_date type="Actual">August 29, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Estimated Glomerular Filtration Rate (eGFR) at 12 Months From Baseline</measure>
    <time_frame>12 months from baseline</time_frame>
    <description>The mean estimated Glomerular Filtration Rate (eGFR) will be calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using serum creatinine measurements and the patient's age, gender, and race. An eGFR below 60 ml/min/1.73 m^2 indicates lower renal function.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Transplant Rejection at 6 Months and 12 Months Post Baseline</measure>
    <time_frame>6 months post baseline, 12 months post baseline</time_frame>
    <description>The number of occurrences of transplant rejection at 6 months and 12 months from baseline will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Grade IIA and Lower Rejections at 6 Months and 12 Months Post Baseline</measure>
    <time_frame>6 months post baseline, 12 months post baseline</time_frame>
    <description>The number of subjects with Grade IIA and lower severity of rejection on the Banff 97 diagnostic categories will be recorded. The severity of acute rejections will be graded based on histopathological findings; Grade IA= significant interstitial infiltration and moderate tubulitis; Grade IB= significant interstitial infiltration and severe tubulitis; Grade IIA= mild to moderate intimal arteritis; Grade IIB= severe intimal arteritis and Grade III= transmural arteritis and/or fibrinoid change and necrosis of cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Grade IIB and Higher Rejections at 6 Months and 12 Months Post Baseline</measure>
    <time_frame>6 months post baseline, 12 months post baseline</time_frame>
    <description>The number of subjects with Grade IIB and higher severity of rejection on the Banff 97 diagnostic categories will be recorded. The severity of acute rejections will be graded based on histopathological findings; Grade IA= significant interstitial infiltration and moderate tubulitis; Grade IB= significant interstitial infiltration and severe tubulitis; Grade IIA= mild to moderate intimal arteritis; Grade IIB= severe intimal arteritis and Grade III= transmural arteritis and/or fibrinoid change and necrosis of cells.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Deaths at 6 Months and 12 Months Post Baseline</measure>
    <time_frame>6 months post baseline, 12 months post baseline</time_frame>
    <description>The total number of subject deaths at 12 months from baseline will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects That Experienced Graft Loss at 6 Moths and 12 Months Post Baseline</measure>
    <time_frame>6 months post baseline, 12 months from baseline</time_frame>
    <description>The total number of subjects who experienced death censored graft loss at 6 months and 12 months from baseline will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects With Human Leukocyte Antigen Donor Specific Antibodies (HLA DSA) at 6 Months and 12 Months Post Baseline</measure>
    <time_frame>6 moths post baseline, 12 months post baseline</time_frame>
    <description>The number of subjects who have circulating human leukocyte antigen donor specific antibodies (HLA DSA) at 12 months from baseline will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Clinic Visits</measure>
    <time_frame>At 12 months from baseline</time_frame>
    <description>The number of clinic visits by the subjects at the end of 12 months from baseline will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Needing Hospitalizations</measure>
    <time_frame>At 12 months from baseline</time_frame>
    <description>The number of subjects who had hospitalizations at the end of 12 months from baseline will be recorded</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Needing Transplant Biopsies at 12 Months Post Baseline</measure>
    <time_frame>12 months post baseline</time_frame>
    <description>The number of subjects needing transplant biopsies at 12 months from baseline will be recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Analysis</measure>
    <time_frame>At 12 months from baseline</time_frame>
    <description>The mean total cost of infusions received by each subject and those associated with round trip travel to the Emory Transplant Center (ETC) will be estimated using the distance between the residential addresses of subjects and the ETC.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">166</enrollment>
  <condition>Kidney Transplantation</condition>
  <arm_group>
    <arm_group_label>Belatacept 8-weekly</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Belatacept 4-weekly</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belatacept</intervention_name>
    <description>Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
    <arm_group_label>Belatacept 4-weekly</arm_group_label>
    <arm_group_label>Belatacept 8-weekly</arm_group_label>
    <other_name>Nulojix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult (age â‰¥18 years currently),&#xD;
&#xD;
          -  First-time renal transplant recipients of either living donor or deceased donor,&#xD;
&#xD;
               1. who were initiated on belatacept at the time of transplant and&#xD;
&#xD;
               2. are at least one year post-transplant and off CNI therapy for at least 6 months.&#xD;
&#xD;
          -  Patients at low immunologic risk, defined as&#xD;
&#xD;
               1. patients with a first transplant who have a PRA &lt; 50 against class I and class II&#xD;
                  antigens,&#xD;
&#xD;
               2. no DSA (donor-specific antibodies),&#xD;
&#xD;
               3. who have not had more than one episode of rejection, and&#xD;
&#xD;
               4. no episodes of rejection within the last 6 months prior to enrollment, and&#xD;
&#xD;
               5. no rejection with a grade of IIB or above.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not first renal transplant, or multi-organ transplant recipient&#xD;
&#xD;
          -  History of greater than one episode of biopsy-proven acute rejection, or of rejection&#xD;
             of Banff 97 grade IIB or greater, or rejection within the last 6 months.&#xD;
&#xD;
          -  Pregnancy (women of childbearing potential must use adequate contraception during&#xD;
             study)&#xD;
&#xD;
          -  Unwilling to receive all belatacept infusions at the Emory Transplant Center&#xD;
&#xD;
          -  Calculated Glomerular Filtration Rate (GFR) less than 35.&#xD;
&#xD;
          -  Serum creatinine at enrollment over 30% higher than 3 months (Â±4 weeks) prior to&#xD;
             randomization&#xD;
&#xD;
          -  HbA1C greater than 8 at enrollment&#xD;
&#xD;
          -  Recent history of significant proteinuria (protein/Cr ratio &gt;1)&#xD;
&#xD;
          -  Non-standard belatacept dosing (e.g. dose other than 5 mg belatacept/kg body weight)&#xD;
&#xD;
          -  Cellcept dose less than 500 mg po bid.&#xD;
&#xD;
          -  Prednisone dose greater than 5mg po qd within 3 months of randomization&#xD;
&#xD;
          -  Patients not currently taking prednisone&#xD;
&#xD;
          -  Active infection, or antibiotic or antiviral drug therapy within 1 month of&#xD;
             randomization&#xD;
&#xD;
          -  Evidence of Cytomegalovirus (CMV) viremia or clinical CMV infection within last 3&#xD;
             months.&#xD;
&#xD;
          -  Polyomavirus BK PCR (polymerase chain reaction) load greater then 4.3 (copy number&#xD;
             greater than 20,0000) within 3 months of randomization&#xD;
&#xD;
          -  Known hepatitis B surface antigen-positive or PCR-positive for hepatitis B (testing&#xD;
             not required)&#xD;
&#xD;
          -  Known HIV (human immunodeficiency virus infection) (testing not required)&#xD;
&#xD;
          -  Presence of donor specific antibody by Luminex single antigen assessment, or panel&#xD;
             reactivity (PRA) above 50%.&#xD;
&#xD;
          -  History of substance abuse or psychiatric disorder not compatible with study adherence&#xD;
             and follow up.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Idelberto Badell, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University Hospital</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>September 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 25, 2015</study_first_posted>
  <results_first_submitted>August 25, 2020</results_first_submitted>
  <results_first_submitted_qc>September 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2020</results_first_posted>
  <last_update_submitted>September 16, 2020</last_update_submitted>
  <last_update_submitted_qc>September 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Idelberto Badell</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Immunosuppression</keyword>
  <keyword>Transplantation Immunology</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 10, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/58/NCT02560558/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Belatacept 8-weekly</title>
          <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
        </group>
        <group group_id="P2">
          <title>Belatacept 4-weekly</title>
          <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="82"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Only included participants that received intervention.</population>
      <group_list>
        <group group_id="B1">
          <title>Belatacept 8-weekly</title>
          <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
        </group>
        <group group_id="B2">
          <title>Belatacept 4-weekly</title>
          <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="82"/>
            <count group_id="B3" value="163"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="13"/>
                    <measurement group_id="B2" value="52" spread="12"/>
                    <measurement group_id="B3" value="51" spread="12.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="46"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Estimated Glomerular Filtration Rate (eGFR) at 12 Months From Baseline</title>
        <description>The mean estimated Glomerular Filtration Rate (eGFR) will be calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using serum creatinine measurements and the patient's age, gender, and race. An eGFR below 60 ml/min/1.73 m^2 indicates lower renal function.</description>
        <time_frame>12 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Estimated Glomerular Filtration Rate (eGFR) at 12 Months From Baseline</title>
          <description>The mean estimated Glomerular Filtration Rate (eGFR) will be calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation using serum creatinine measurements and the patient's age, gender, and race. An eGFR below 60 ml/min/1.73 m^2 indicates lower renal function.</description>
          <units>ml/min/1.73m^2</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.13" lower_limit="70.14" upper_limit="74.12"/>
                    <measurement group_id="O2" value="72.65" lower_limit="70.64" upper_limit="74.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Transplant Rejection at 6 Months and 12 Months Post Baseline</title>
        <description>The number of occurrences of transplant rejection at 6 months and 12 months from baseline will be recorded.</description>
        <time_frame>6 months post baseline, 12 months post baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Transplant Rejection at 6 Months and 12 Months Post Baseline</title>
          <description>The number of occurrences of transplant rejection at 6 months and 12 months from baseline will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Grade IIA and Lower Rejections at 6 Months and 12 Months Post Baseline</title>
        <description>The number of subjects with Grade IIA and lower severity of rejection on the Banff 97 diagnostic categories will be recorded. The severity of acute rejections will be graded based on histopathological findings; Grade IA= significant interstitial infiltration and moderate tubulitis; Grade IB= significant interstitial infiltration and severe tubulitis; Grade IIA= mild to moderate intimal arteritis; Grade IIB= severe intimal arteritis and Grade III= transmural arteritis and/or fibrinoid change and necrosis of cells.</description>
        <time_frame>6 months post baseline, 12 months post baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Grade IIA and Lower Rejections at 6 Months and 12 Months Post Baseline</title>
          <description>The number of subjects with Grade IIA and lower severity of rejection on the Banff 97 diagnostic categories will be recorded. The severity of acute rejections will be graded based on histopathological findings; Grade IA= significant interstitial infiltration and moderate tubulitis; Grade IB= significant interstitial infiltration and severe tubulitis; Grade IIA= mild to moderate intimal arteritis; Grade IIB= severe intimal arteritis and Grade III= transmural arteritis and/or fibrinoid change and necrosis of cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Grade IIB and Higher Rejections at 6 Months and 12 Months Post Baseline</title>
        <description>The number of subjects with Grade IIB and higher severity of rejection on the Banff 97 diagnostic categories will be recorded. The severity of acute rejections will be graded based on histopathological findings; Grade IA= significant interstitial infiltration and moderate tubulitis; Grade IB= significant interstitial infiltration and severe tubulitis; Grade IIA= mild to moderate intimal arteritis; Grade IIB= severe intimal arteritis and Grade III= transmural arteritis and/or fibrinoid change and necrosis of cells.</description>
        <time_frame>6 months post baseline, 12 months post baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Grade IIB and Higher Rejections at 6 Months and 12 Months Post Baseline</title>
          <description>The number of subjects with Grade IIB and higher severity of rejection on the Banff 97 diagnostic categories will be recorded. The severity of acute rejections will be graded based on histopathological findings; Grade IA= significant interstitial infiltration and moderate tubulitis; Grade IB= significant interstitial infiltration and severe tubulitis; Grade IIA= mild to moderate intimal arteritis; Grade IIB= severe intimal arteritis and Grade III= transmural arteritis and/or fibrinoid change and necrosis of cells.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Deaths at 6 Months and 12 Months Post Baseline</title>
        <description>The total number of subject deaths at 12 months from baseline will be recorded.</description>
        <time_frame>6 months post baseline, 12 months post baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Deaths at 6 Months and 12 Months Post Baseline</title>
          <description>The total number of subject deaths at 12 months from baseline will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects That Experienced Graft Loss at 6 Moths and 12 Months Post Baseline</title>
        <description>The total number of subjects who experienced death censored graft loss at 6 months and 12 months from baseline will be recorded.</description>
        <time_frame>6 months post baseline, 12 months from baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects That Experienced Graft Loss at 6 Moths and 12 Months Post Baseline</title>
          <description>The total number of subjects who experienced death censored graft loss at 6 months and 12 months from baseline will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects With Human Leukocyte Antigen Donor Specific Antibodies (HLA DSA) at 6 Months and 12 Months Post Baseline</title>
        <description>The number of subjects who have circulating human leukocyte antigen donor specific antibodies (HLA DSA) at 12 months from baseline will be recorded.</description>
        <time_frame>6 moths post baseline, 12 months post baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects With Human Leukocyte Antigen Donor Specific Antibodies (HLA DSA) at 6 Months and 12 Months Post Baseline</title>
          <description>The number of subjects who have circulating human leukocyte antigen donor specific antibodies (HLA DSA) at 12 months from baseline will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months post baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Clinic Visits</title>
        <description>The number of clinic visits by the subjects at the end of 12 months from baseline will be recorded.</description>
        <time_frame>At 12 months from baseline</time_frame>
        <population>Resources/tools not available for recording/tracking the data required to reliably report the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Clinic Visits</title>
          <description>The number of clinic visits by the subjects at the end of 12 months from baseline will be recorded.</description>
          <population>Resources/tools not available for recording/tracking the data required to reliably report the outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Needing Hospitalizations</title>
        <description>The number of subjects who had hospitalizations at the end of 12 months from baseline will be recorded</description>
        <time_frame>At 12 months from baseline</time_frame>
        <population>Resources/tools not available for recording/tracking the data required to reliably report the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Needing Hospitalizations</title>
          <description>The number of subjects who had hospitalizations at the end of 12 months from baseline will be recorded</description>
          <population>Resources/tools not available for recording/tracking the data required to reliably report the outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Needing Transplant Biopsies at 12 Months Post Baseline</title>
        <description>The number of subjects needing transplant biopsies at 12 months from baseline will be recorded.</description>
        <time_frame>12 months post baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Needing Transplant Biopsies at 12 Months Post Baseline</title>
          <description>The number of subjects needing transplant biopsies at 12 months from baseline will be recorded.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cost Analysis</title>
        <description>The mean total cost of infusions received by each subject and those associated with round trip travel to the Emory Transplant Center (ETC) will be estimated using the distance between the residential addresses of subjects and the ETC.</description>
        <time_frame>At 12 months from baseline</time_frame>
        <population>Resources/tools not available for recording/tracking the data required to reliably report the outcome.</population>
        <group_list>
          <group group_id="O1">
            <title>Belatacept 8-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
          <group group_id="O2">
            <title>Belatacept 4-weekly</title>
            <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Cost Analysis</title>
          <description>The mean total cost of infusions received by each subject and those associated with round trip travel to the Emory Transplant Center (ETC) will be estimated using the distance between the residential addresses of subjects and the ETC.</description>
          <population>Resources/tools not available for recording/tracking the data required to reliably report the outcome.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 12 months post baseline</time_frame>
      <desc>Adverse events were captured through active surveillance via open ended questions by the research coordinator at each study visit in accordance with the Common Terminology Criteria for Adverse Events (CTCAE)</desc>
      <group_list>
        <group group_id="E1">
          <title>Belatacept 8-weekly</title>
          <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 8 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
        </group>
        <group group_id="E2">
          <title>Belatacept 4-weekly</title>
          <description>Subjects who are stable on belatacept therapy at least one year after a renal transplant will receive belatacept infusion intravenously (IV) at 5 mg/kg every 4 weeks.&#xD;
Belatacept: Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="76"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non Infectious severe Adverse Events</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious Severe Adverse Events</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="81"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Other</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infectious Adverse Events</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="81"/>
                <counts group_id="E2" events="30" subjects_affected="24" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Non melanoma skin cancer</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="82"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Idelberto Badell</name_or_title>
      <organization>Emory University</organization>
      <phone>404-712-6562</phone>
      <email>ibadell@emory.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

